Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia

Yuri Miyazaki, Kazuaki Taguchi, Keitaro Sou, Hiroshi Watanabe, Yu Ishima, Toshikazu Miyakawa, Hiroaki Mitsuya, Masafumi Fukagawa, Masaki Otagiri, Toru Maruyama

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

(Figure Presented). Bone marrow is a key element in the diagnosis of disorders of erythropoiesis, including anemia, and a potential target in their treatment. However, because efficient delivery of diagnostic and therapeutic agents to bone marrow is difficult, such delivery is achieved by administering drugs in large quantities that often have adverse effects. Here, we achieved selective delivery of recombinant human erythropoietin (rHuEPO) to bone marrow, via its encapsulation in liposomes with L-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) (liposome-EPO). The result, in a rabbit model of renal anemia, was a beneficial effect on hematopoiesis, better than with rHuEPO alone. Also, we determined that liposome-EPO delivery to bone marrow depended on specific uptake by bone marrow macrophages because of the presence of SA. These results indicate both that liposome-EPO is a new, promising erythropoietin-stimulating agent and that liposomes with SA have potential for diagnostic and therapeutic applications in diseases originating from bone marrow.

Original languageEnglish
Pages (from-to)4238-4248
Number of pages11
JournalMolecular Pharmaceutics
Volume11
Issue number11
DOIs
Publication statusPublished - 2014 Sep 25
Externally publishedYes

Fingerprint

Erythropoietin
Liposomes
Anemia
Bone Marrow
Kidney
Bone Marrow Diseases
Therapeutics
Erythropoiesis
Hematopoiesis
Glutamic Acid
Esters
Macrophages
Rabbits
Pharmaceutical Preparations

Keywords

  • Bone marrow
  • Erythropoietin
  • Liposome
  • Macrophages

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Miyazaki, Y., Taguchi, K., Sou, K., Watanabe, H., Ishima, Y., Miyakawa, T., ... Maruyama, T. (2014). Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia. Molecular Pharmaceutics, 11(11), 4238-4248. https://doi.org/10.1021/mp500453a

Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia. / Miyazaki, Yuri; Taguchi, Kazuaki; Sou, Keitaro; Watanabe, Hiroshi; Ishima, Yu; Miyakawa, Toshikazu; Mitsuya, Hiroaki; Fukagawa, Masafumi; Otagiri, Masaki; Maruyama, Toru.

In: Molecular Pharmaceutics, Vol. 11, No. 11, 25.09.2014, p. 4238-4248.

Research output: Contribution to journalArticle

Miyazaki, Y, Taguchi, K, Sou, K, Watanabe, H, Ishima, Y, Miyakawa, T, Mitsuya, H, Fukagawa, M, Otagiri, M & Maruyama, T 2014, 'Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia', Molecular Pharmaceutics, vol. 11, no. 11, pp. 4238-4248. https://doi.org/10.1021/mp500453a
Miyazaki Y, Taguchi K, Sou K, Watanabe H, Ishima Y, Miyakawa T et al. Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia. Molecular Pharmaceutics. 2014 Sep 25;11(11):4238-4248. https://doi.org/10.1021/mp500453a
Miyazaki, Yuri ; Taguchi, Kazuaki ; Sou, Keitaro ; Watanabe, Hiroshi ; Ishima, Yu ; Miyakawa, Toshikazu ; Mitsuya, Hiroaki ; Fukagawa, Masafumi ; Otagiri, Masaki ; Maruyama, Toru. / Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia. In: Molecular Pharmaceutics. 2014 ; Vol. 11, No. 11. pp. 4238-4248.
@article{42763808221949bbbd54fb5c158758b5,
title = "Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia",
abstract = "(Figure Presented). Bone marrow is a key element in the diagnosis of disorders of erythropoiesis, including anemia, and a potential target in their treatment. However, because efficient delivery of diagnostic and therapeutic agents to bone marrow is difficult, such delivery is achieved by administering drugs in large quantities that often have adverse effects. Here, we achieved selective delivery of recombinant human erythropoietin (rHuEPO) to bone marrow, via its encapsulation in liposomes with L-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) (liposome-EPO). The result, in a rabbit model of renal anemia, was a beneficial effect on hematopoiesis, better than with rHuEPO alone. Also, we determined that liposome-EPO delivery to bone marrow depended on specific uptake by bone marrow macrophages because of the presence of SA. These results indicate both that liposome-EPO is a new, promising erythropoietin-stimulating agent and that liposomes with SA have potential for diagnostic and therapeutic applications in diseases originating from bone marrow.",
keywords = "Bone marrow, Erythropoietin, Liposome, Macrophages",
author = "Yuri Miyazaki and Kazuaki Taguchi and Keitaro Sou and Hiroshi Watanabe and Yu Ishima and Toshikazu Miyakawa and Hiroaki Mitsuya and Masafumi Fukagawa and Masaki Otagiri and Toru Maruyama",
year = "2014",
month = "9",
day = "25",
doi = "10.1021/mp500453a",
language = "English",
volume = "11",
pages = "4238--4248",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia

AU - Miyazaki, Yuri

AU - Taguchi, Kazuaki

AU - Sou, Keitaro

AU - Watanabe, Hiroshi

AU - Ishima, Yu

AU - Miyakawa, Toshikazu

AU - Mitsuya, Hiroaki

AU - Fukagawa, Masafumi

AU - Otagiri, Masaki

AU - Maruyama, Toru

PY - 2014/9/25

Y1 - 2014/9/25

N2 - (Figure Presented). Bone marrow is a key element in the diagnosis of disorders of erythropoiesis, including anemia, and a potential target in their treatment. However, because efficient delivery of diagnostic and therapeutic agents to bone marrow is difficult, such delivery is achieved by administering drugs in large quantities that often have adverse effects. Here, we achieved selective delivery of recombinant human erythropoietin (rHuEPO) to bone marrow, via its encapsulation in liposomes with L-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) (liposome-EPO). The result, in a rabbit model of renal anemia, was a beneficial effect on hematopoiesis, better than with rHuEPO alone. Also, we determined that liposome-EPO delivery to bone marrow depended on specific uptake by bone marrow macrophages because of the presence of SA. These results indicate both that liposome-EPO is a new, promising erythropoietin-stimulating agent and that liposomes with SA have potential for diagnostic and therapeutic applications in diseases originating from bone marrow.

AB - (Figure Presented). Bone marrow is a key element in the diagnosis of disorders of erythropoiesis, including anemia, and a potential target in their treatment. However, because efficient delivery of diagnostic and therapeutic agents to bone marrow is difficult, such delivery is achieved by administering drugs in large quantities that often have adverse effects. Here, we achieved selective delivery of recombinant human erythropoietin (rHuEPO) to bone marrow, via its encapsulation in liposomes with L-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA) (liposome-EPO). The result, in a rabbit model of renal anemia, was a beneficial effect on hematopoiesis, better than with rHuEPO alone. Also, we determined that liposome-EPO delivery to bone marrow depended on specific uptake by bone marrow macrophages because of the presence of SA. These results indicate both that liposome-EPO is a new, promising erythropoietin-stimulating agent and that liposomes with SA have potential for diagnostic and therapeutic applications in diseases originating from bone marrow.

KW - Bone marrow

KW - Erythropoietin

KW - Liposome

KW - Macrophages

UR - http://www.scopus.com/inward/record.url?scp=84928384645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928384645&partnerID=8YFLogxK

U2 - 10.1021/mp500453a

DO - 10.1021/mp500453a

M3 - Article

VL - 11

SP - 4238

EP - 4248

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 11

ER -